Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive systemic sclerosis and the lung.

S Veeraraghavan1, O P Sharma

  • 1Division of Pulmonary and Critical Care Medicine, Los Angeles, CA 90033, USA.

Current Opinion in Pulmonary Medicine
|May 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can I Interview Her? Gatekeeping in a Telephone Survey of Female Migrants in India.

Survey practice·2025
Same author

Occult hepatitis B virus infection among chronic liver disease patients: Insights from a tertiary care hospital.

Indian journal of medical microbiology·2025
Same author

An Indian Consensus on Sarcopenia: Epidemiology, Etiology, Clinical Impact, Screening, and Therapeutic Approaches.

International journal of general medicine·2025
Same author

Gone and Forgotten? Predictors of Birth History Omissions in India.

Demographic research·2024
Same author

Tuberculosis in elderly persons.

The Indian journal of tuberculosis·2022
Same author

Diagnoses and management of adult cough: An Indian Environmental Medical Association (EMA) position paper.

Respiratory medicine·2020
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
Same journal

Advancing lung transplantation: current challenges and future directions.

Current opinion in pulmonary medicine·2026
Same journal

Association between upper airway obstruction and pulmonary hypertension in children with Down syndrome.

Current opinion in pulmonary medicine·2026
Same journal

Molecular mechanisms of environmental risk factors for interstitial lung disease.

Current opinion in pulmonary medicine·2026
See all related articles

Systemic sclerosis, or scleroderma, often affects the lungs, leading to a poor prognosis. Enhancing diagnostic methods and treatments is crucial for improving survival rates in patients with scleroderma lung disease.

Area of Science:

  • Pulmonary medicine
  • Rheumatology
  • Systemic autoimmune diseases

Background:

  • Systemic sclerosis (scleroderma) is a chronic autoimmune disease characterized by widespread fibrosis affecting multiple organs.
  • Pulmonary involvement is a common and serious complication of systemic sclerosis, significantly impacting patient morbidity and mortality.
  • Scleroderma lung disease encompasses a range of pathological changes, including interstitial lung disease and pulmonary arterial hypertension.

Purpose of the Study:

  • To review the pulmonary manifestations of systemic sclerosis.
  • To highlight the current survival statistics for patients with scleroderma lung disease.
  • To emphasize the urgent need for advancements in diagnostic and therapeutic strategies.

Main Methods:

  • Literature review of pulmonary manifestations in systemic sclerosis.

Related Experiment Videos

  • Analysis of survival data in patients with scleroderma lung disease.
  • Discussion of current diagnostic and therapeutic challenges.

    • Main Results:

    • Pulmonary complications are a frequent and significant feature of systemic sclerosis.
    • The mean survival for patients with scleroderma lung disease is approximately 78 months (± 17 months).
    • High mortality rates underscore the severity of this condition.

    Conclusions:

    • Pulmonary involvement in systemic sclerosis presents a major clinical challenge.
    • There is a critical need for improved diagnostic tools to detect lung disease early.
    • Enhanced therapeutic interventions are essential to reduce the mortality associated with scleroderma lung disease.